Skip to main content

Table 3 Evaluation of response in osimertinib treatment patients according to T790M status by tag-based NGS

From: Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients

Patient Sex Age (yrs, median 71) Sensitizing EGFR mut osimertinib, response plasma T790M
Real Time PCR tag-based NGS
24 M 58 exon 19 del PR pos pos
27 F 74 L858R PD pos pos
25 F 71 L858R SD neg pos
14 F 75 exon 19 del SD neg nega
35 M 64 exon 19 del PR neg pos
26 F 66 L858R PR neg pos
15 M 75 L858R SD neg pos
2 M 71 exon 19 del PR neg pos
18 F 72 exon 19 del PR pos pos
6 M 78 exon 19 del PR pos pos
10 F 71 exon 19 del PR pos pos
36 F 85 exon 19 del SD pos pos
37 F 65 exon 19 del PR pos pos
39 M 75 G719C PR pos pos
33 F 82 L858R not evaluable neg pos
16 F 66 exon 19 del SD neg pos
22 F 62 exon 20 ins SD neg pos
  1. del deletion, PR Partial Response, PD Progressive Disease, SD Stable Disease, pos positive, neg negative
  2. athis patient has been treated with third generation TKI because of T790M-positivity in post-TKI tissue